Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.

Literature DB >> 25048969

Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.

Laura Zanotti¹, Alberto Bottini, Camillo Rossi, Daniele Generali, Maria Rosa Cappelletti.

Abstract

Breast cancer is a complex disease with heterogeneous presentation and clinical course. The last decade has witnessed the development, commercialization, and increasing use of multigene assays, designed to support physicians and patients in clinical decision making in early-stage breast cancer. These include Oncotype DX®, MammaPrint®, and Prosigna™ assays. The assays differ in the technological platforms used for assessment of gene expression, in the number of genes and in the specific genes that are being tested, in the patient populations used for their development and validation, and in their clinical utility. This review focuses on these three commercialized assays, their development, validation, and clinical utility. The review also addresses ongoing prospective trials investigating these assays and health-economic considerations relating to their use.

Entities: Disease Species

Mesh：

Year: 2014 PMID： 25048969 DOI： 10.1007/s13277-014-2366-2

Source DB: PubMed Journal: Tumour Biol ISSN： 1010-4283

66 in total

1. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.

Authors: John Hornberger; Leon E Cosler; Gary H Lyman
Journal: Am J Manag Care Date: 2005-05 Impact factor: 2.229

2. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.

Authors: Stella Mook; Marjanka K Schmidt; Giuseppe Viale; Giancarlo Pruneri; Inge Eekhout; Arno Floore; Annuska M Glas; Jan Bogaerts; Fatima Cardoso; Martine J Piccart-Gebhart; Emiel T Rutgers; Laura J Van't Veer
Journal: Breast Cancer Res Treat Date: 2008-07-27 Impact factor: 4.872

3. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.

Authors: M Gnant; I Sestak; M Filipits; M Dowsett; M Balic; E Lopez-Knowles; R Greil; P Dubsky; H Stoeger; M Rudas; R Jakesz; S Ferree; J W Cowens; T Nielsen; C Schaper; C Fesl; J Cuzick
Journal: Ann Oncol Date: 2015-05-01 Impact factor: 32.976

Review 4. Histological, molecular and functional subtypes of breast cancers.

Authors: Gautam K Malhotra; Xiangshan Zhao; Hamid Band; Vimla Band
Journal: Cancer Biol Ther Date: 2010-11-15 Impact factor: 4.742

5. Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer.

Authors: Daphne T Tsoi; Miho Inoue; Catherine M Kelly; Sunil Verma; Kathleen I Pritchard
Journal: Oncologist Date: 2010-04-26

6. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.

Authors: Martin Filipits; Torsten O Nielsen; Margaretha Rudas; Richard Greil; Herbert Stöger; Raimund Jakesz; Zsuzsanna Bago-Horvath; Otto Dietze; Peter Regitnig; Christine Gruber-Rossipal; Elisabeth Müller-Holzner; Christian F Singer; Brigitte Mlineritsch; Peter Dubsky; Thomas Bauernhofer; Michael Hubalek; Michael Knauer; Harald Trapl; Christian Fesl; Carl Schaper; Sean Ferree; Shuzhen Liu; J Wayne Cowens; Michael Gnant
Journal: Clin Cancer Res Date: 2014-02-11 Impact factor: 12.531

7. A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer.

Authors: J A Davidson; I Cromwell; S L Ellard; C Lohrisch; K A Gelmon; T Shenkier; D Villa; H Lim; S Sun; S Taylor; M Taylor; B Czerkawski; M Hayes; D N Ionescu; C Yoshizawa; C Chao; S Peacock; S K Chia
Journal: Eur J Cancer Date: 2013-04-20 Impact factor: 9.162

8. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

Authors: Jolien M Bueno-de-Mesquita; Wim H van Harten; Valesca P Retel; Laura J van 't Veer; Frits Sam van Dam; Kim Karsenberg; Kirsten Fl Douma; Harm van Tinteren; Johannes L Peterse; Jelle Wesseling; Tin S Wu; Douwe Atsma; Emiel Jt Rutgers; Guido Brink; Arno N Floore; Annuska M Glas; Rudi Mh Roumen; Frank E Bellot; Cees van Krimpen; Sjoerd Rodenhuis; Marc J van de Vijver; Sabine C Linn
Journal: Lancet Oncol Date: 2007-11-26 Impact factor: 41.316

9. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.

Authors: R Peto; C Davies; J Godwin; R Gray; H C Pan; M Clarke; D Cutter; S Darby; P McGale; C Taylor; Y C Wang; J Bergh; A Di Leo; K Albain; S Swain; M Piccart; K Pritchard
Journal: Lancet Date: 2011-12-05 Impact factor: 79.321

10. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.

Authors: Mitch Dowsett; Ivana Sestak; Elena Lopez-Knowles; Kalvinder Sidhu; Anita K Dunbier; J Wayne Cowens; Sean Ferree; James Storhoff; Carl Schaper; Jack Cuzick
Journal: J Clin Oncol Date: 2013-07-01 Impact factor: 44.544

8 in total

Review 1. Mechanisms of aromatase inhibitor resistance.

Authors: Cynthia X Ma; Tomás Reinert; Izabela Chmielewska; Matthew J Ellis
Journal: Nat Rev Cancer Date: 2015-05 Impact factor: 60.716

2. Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years.

Authors: Arnold L Potosky; Suzanne C O'Neill; Claudine Isaacs; Huei-Ting Tsai; Calvin Chao; Chunfu Liu; Bola F Ekezue; Nandini Selvam; Larry G Kessler; Yingjun Zhou; Marc D Schwartz
Journal: Cancer Date: 2015-08-20 Impact factor: 6.860

Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.

1. Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.

2. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.

3. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.

Review 4. Histological, molecular and functional subtypes of breast cancers.

5. Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer.

6. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.

7. A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer.

8. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

9. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.

10. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.

Review 1. Mechanisms of aromatase inhibitor resistance.

2. Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years.

3. Adjuvant Chemotherapy Use and Health Care Costs After Introduction of Genomic Testing in Breast Cancer.

Review 4. Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.

5. Differential CARM1 Isoform Expression in Subcellular Compartments and among Malignant and Benign Breast Tumors.

6. Transcriptome Analysis Identifies the Dysregulation of Ultraviolet Target Genes in Human Skin Cancers.

Review 7. Molecular pathology of cancer: how to communicate with disease.

Review 8. Taking Bioinformatics to Systems Medicine.